The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 2, 2006, Pages 103-110

  Hedaya, Mohsen A ^a   El Afify, Dalia R ^a   El Maghraby, Gamal M ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Bioavailability; CYP3A4 inhibitors; Pharmacokinetic interactions; Sildenafil

Indexed keywords

CIPROFLOXACIN; CLARIBIOTIC; CLARITHROMYCIN; CYTOCHROME P450 3A4; SILDENAFIL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ERECTILE DYSFUNCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; LIVER; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 33645287695     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.488     Document Type: Article

References (21)

1. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effect of sildenafil on relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes. J Urol 1998; 159: 2164-2171.
2. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C-44C.
3. Cheitlin MD, Hutter AM Jr. Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273-282.
4. Krenzolok EP. Sildenafil: clinical toxicology profile. J Toxicol Clin Toxicol 2000; 38: 645-651.
5. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53(Suppl): 5S-12S.
6. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000; 28: 392-397.
7. Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51: 239-248.
8. Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol 2002; 53(Suppl): 31S-36S.
9. Muirhead GJ, Faulken S, Harness JA, Taubel J. The effect of steady state erythromycin and azithromycin on pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002; 53(Suppl): 37S-43S.
10. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
11. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002; 71: 21-29.
12. McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24: 1134-1138.
13. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356: 2069-2070.
14. Bruce MA, Hall SD, Daniels BD, Corski JC. In vivo effect of clarithromycin on multiple cytochrome P450. Drug Metab Dispos 2001; 29: 1023-1028.
15. Oberg KC. Delayed elevation of international normalization ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy 1998; 18: 386-391.
16. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 29: 323-328.
17. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 2004; 78: 1496-1506.
18. Brophy DF, Israel DS, Pastor A, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000; 44: 978-984.
19. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31.
20. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001; 88: 187-191.
21. Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001; 70: 58-65.